Regulatory Strategy Consultation for SaMD

Achieving rapid and compliant market access for Software as a Medical Device (SaMD) requires a well defined, region specific regulatory strategy. As digital health expands with AI driven diagnostics, continuous monitoring technologies, and mobile health platforms, regulatory expectations have become increasingly intricate. Masuu Global Solutions simplifies this complexity, creating a clear pathway for global compliance.

Overview

At Masuu Global Solutions, we help organizations navigate the full spectrum of SaMD regulatory requirements. Our expert teams deliver end to end compliance support, addressing major international standards including IEC 62304, ISO 13485, ISO 14971, and EU MDR/IVDR expectations.

We streamline approvals across key markets such as the United States and European Union, offering hands on guidance for FDA 510(k) pathways and CE marking processes. By aligning your software design, documentation, risk management, and clinical evidence with regional requirements, we accelerate your global launch while reducing regulatory risk.

With deep experience in regulatory strategy, gap assessment, technical documentation, and risk controls, Masuu Global Solutions serves as your partner through every stage of SaMD commercialization—from classification to global market harmonization.

Regulatory Strategy Consultation Services

Our consulting services are fully aligned with your SaMD’s intended use, target markets, and risk profile.

Our Services Include:

  • Comprehensive evaluation of your SaMD’s purpose, functionality, and market goals
  • Detailed review of technical documentation with gap identification
  • Country specific risk classification based on regional frameworks
  • Mapping of relevant global standards (ISO 13485, IEC 62304, IEC 82304 1, etc.)
  • Identification of suitable regulatory pathways such as 510(k), CE marking, MDL, Shonin/Ninsho, and others

Every output is customized to the product, region, and commercialization timeline.

Regulatory Pathways & In Country Representation

Masuu Global Solutions supports SaMD market entry across key international regions:
  • United States (FDA): SaMD qualification, 510(k), De Novo, and PMA submissions
  • European Union (EU MDR): Classification of Medical Device Software (MDSW), CE marking for Classes I–IIIi>
  • Japan (PMDA): Ninsho and Shonin pathways for Class II/III SaMD
  • Global Markets: Support for APAC, LATAM, Middle East, and additional regions

Where required, Masuu also serves as your local regulatory representative, ensuring seamless communication with authorities and maintaining regional compliance.

Regulatory Intelligence & Roadmap Development

We provide real time, forward looking intelligence to help your SaMD stay ahead of evolving regulations.

Our Services Include:

  • Ongoing updates on changes in FDA guidance, MDCG publications, PMDA revisions, MFDS updates, etc.
  • Horizon scanning for emerging AI/ML related regulatory trends
  • Competitor pathway analysis and benchmarking
  • Creation of detailed regulatory roadmaps aligned with your launch plans

Our strategic roadmaps outline key milestones across pre submission, documentation, submission, and post approval phases—helping you plan budgets, predict timelines, and manage risks.

Global Strategy & Market Expansion

Beyond single market compliance, Masuu empowers companies to scale their SaMD internationally.

Our Cross Market Services Include:

  • Comparative regulatory mapping across more than 10 global regions
  • Document reuse and adaptation strategy
  • Input from cybersecurity, clinical, and QMS specialists
  • Tailored support for synchronized multi market submissions

As digital health becomes globally interconnected, scalable regulatory planning becomes essential to growth. Masuu ensures your SaMD is built for expansion.

Challenges vs. Your Benefits with Masuu’s SaMD Solutions

Complex & Evolving Regulations

Regulations such as FDA QSR, EU MDR, ISO 13485, ISO 14971, IEC 62304, and privacy laws can delay development without a structured QMS.

Your Benefits:
  • Fast, audit ready compliance
  • Immediate access to ISO aligned QMS frameworks

High Costs & Fragmented Efforts

Coordinating expertise across Notified Bodies, consultants, and authorities increases costs and creates inefficiencies.

Your Benefits:
  • Full QARA team at a predictable monthly cost
  • Over 50% cost savings vs. building in house teams
  • Full regulatory coverage at less than the cost of one internal FTE

Long & Risk Prone Timelines

QMS setup, CE approvals, and FDA submissions often stretch into months or years.

Your Benefits:
  • Cut 6+ months from QMS and ISO certification timelines
  • Avoid rework through expert led documentation
  • Save €50K+ on QMS and eQMS implementation
  • Proven success rate across global SaMD registrations

Frequently Asked Questions

The regulatory pathway depends on the SaMD’s intended use, functionality, risk profile, classification, and target market. The strategy typically begins with qualification and classification, followed by identification of applicable standards, clinical evidence, technical documentation, and the appropriate submission or conformity pathway for the specific jurisdiction.

SaMD classification is determined using the regulatory framework applicable in each jurisdiction. The FDA evaluates software according to its intended use and regulatory risk, while EU MDR applies specific classification rules for medical device software. A product may therefore require separate classification assessments for U.S. and European market entry.

The appropriate FDA pathway depends on the SaMD’s risk, intended use, technological characteristics, and whether a suitable predicate device exists. A 510(k) may apply when substantial equivalence can be established, while De Novo can address certain novel devices without predicates and PMA applies to higher-risk devices requiring premarket approval.

SaMD entering the European Union must first be qualified and classified under the EU MDR framework. Depending on its classification, the manufacturer may need an applicable conformity assessment involving a Notified Body before CE marking. Technical documentation, clinical evaluation, risk management, quality systems, and post-market requirements must also be addressed.

A regulatory strategy assessment should review the SaMD’s intended purpose, product functionality, technical documentation, software architecture, risk management information, clinical evidence, quality system documentation, cybersecurity information, and existing approvals. Reviewing these materials helps identify regulatory gaps and determine the appropriate pathway for each target market.

Key standards identified for SaMD regulatory planning include ISO 13485 for quality management, IEC 62304 for software lifecycle processes, ISO 14971 for risk management, and IEC 82304-1 for health software safety. The applicable standards should be mapped against the product, intended use, risk profile, and regulatory requirements of each market.

A global SaMD regulatory roadmap should define target markets, qualification and classification activities, applicable standards, clinical and technical evidence requirements, QMS needs, submission milestones, and post-approval obligations. Comparing requirements across markets also helps determine which documents can be reused and which require country-specific adaptation.

Regulatory gap analysis compares the existing SaMD documentation, development processes, risk controls, clinical evidence, and quality systems against the requirements of the intended market. It can identify missing or inadequate evidence, documentation, standards, or controls before submission, helping reduce the likelihood of deficiencies and regulatory rework.

AI-based SaMD requires consideration of its intended medical purpose, risk classification, clinical evidence, software lifecycle controls, risk management, and applicable AI or machine-learning guidance. Regulatory planning should also consider evolving requirements and cybersecurity expectations. The specific evidence and documentation needed depend on the product and target jurisdiction.

Some SaMD documentation can potentially be reused across markets, particularly core software lifecycle, risk management, clinical, and QMS records. However, regulatory authorities can have different submission formats, classification rules, evidence expectations, and local requirements. A document reuse and adaptation strategy helps identify common materials and required country-specific changes.

Book a Demo